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Abstract: About 10-15% of clinically recognized pregnancies end in a miscarriage. Recurrent miscarriage defined as 
loss of three or more consecutive pregnancies complicate about 1-2% of couples trying to conceive. The most common 
cause of miscarriage is chromosomal aberration in the fetus. However in a vast majority, the cause of miscarriages 
remain unknown. This makes treatment options difficult and often empirical. It has been postulated that a causative 
factor in many cases of miscarriage may be inadequate secretion of progesterone during the luteal phase of the 
menstrual cycle and in the early weeks of pregnancy. Therefore, progestogens have been used, beginning in the first 
trimester of pregnancy, in an attempt to prevent spontaneous miscarriages. In women presenting with a clinical 
diagnosis of threatened miscarriage, there is preliminary evidence of a reduction in the rate of spontaneous miscarriage 
with the use of progesterone. Larger RCTs may help to validate these findings. Initial reports of favourable outcome with 
use of progesterone in recurrent pregnancy loss (RPL) could not be confirmed uniformly by larger randomized trials. This 
article aims at reviewing the role of progesterone in treatment of threatened and recurrent miscarriages. 
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INTRODUCTION 
Human reproduction is associated with a high risk of 
pregnancy loss. Almost 60% of fertilized ova do not 
reach the stage of clinically recognized pregnancy; 
resulting in occult miscarriage either due to immediate 
demise of the fertilized ova or failed implantation of the 
blastocyst [1-3]. In addition to this about 10-15% of 
clinically recognized pregnancies end in a miscarriage 
[4]. 
The term miscarriage refers to spontaneous loss of 
pregnancy prior to twenty weeks of gestation (i.e. prior 
to the age of fetal viability). Vaginal bleeding in the first 
twenty weeks of pregnancy: ranging from mild spotting 
to profuse bleeding along with pain or without pain is 
known as threatened miscarriage. Pregnancy loss in 
first 20 weeks, after appearance of fetal cardiac activity 
affects less than 5% of pregnancies [5]. When bleeding 
is associated with cervical dilatation miscarriage is 
inevitable. Recurrent miscarriage defined as loss of 
three or more consecutive pregnancies complicate 
about 1-2% of couples trying to conceive [6, 7]. 
The most common cause of miscarriage (in < 50%) 
is chromosomal aberration in the fetus [8, 9]. Other risk 
factors include- advanced maternal age, obesity, 
multiple gestation and acute infections. Pregnancy loss 
may be recurrent due to autoimmune factors (such as 
phospholipid antibodies, lupus anticoagulant and 
cardiolipin antibodies), genetic disorders, polycystic 
ovaries, poorly controlled diabetes, thyroid dysfunction, 
 
 
*Address correspondence to this author at the Senior Consultant Department of 
OBGYN, Tata Main Hospital India; Tel: +916572441344;  
E-mail: E-mail: alokanandaray@yahoo.com 
uterine anomalies and thrombophillias. However in 
more than 50% couples the cause of recurrent 
miscarriages remain unknown. This makes treatment 
options difficult and often empirical.  
Pregnancies complicated with threatened 
miscarriage are 2.6 times more likely to miscarry and 
are often associated with adverse pregnancy outcomes 
such as- placenta previa, placental abruption, preterm 
labour, fetal growth restriction, low birth weight, 
caesarean section and increased risk of perinatal 
mortality [10]. Research shows that - miscarriage can 
result in significant emotional and physical stress to 
both partners [11, 12]. Needless to say the financial 
impact of miscarriage to any health care system can be 
substantial.  
A considerable body of evidence now suggest that a 
shift from T-helper 2 (Th2)-dependent anti-
inflammatory cytokines to T-helper 1 (Th1)-mediated 
production of pro-inflammatory cytokines is seen in 
aborted pregnancies. Studies have indicated an 
association between Th1 mediated immune responses 
and reproductive failure [13]. Tumor necrosis factor 
α(TNFα) which is a Th1-dependent pro-inflammatory 
cytokine initiates cytotoxic activity resulting in 
trophoblast apoptosis [14, 15]. An increase in the Th1-
dependent production of IL-12 and a decrease in the 
expression of anti-inflammatory cytokine Interleukin 
(IL)-10, can activate maternal lymphocytes and result in 
pregnancy loss. On the other hand a high level of IL-10 
production is protective with favourable pregnancy 
outcome. [16]. Women suffering from repeated 
spontaneous miscarriages, differ in the Th1/Th2 
cytokine ratio compared with women who do not have 
RPLs; e.g.: The ratio of interferon (IFNγ)- /interleukin 
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(IL)-10 produced by mitogen-stimulated peripheral 
blood mononuclear cells (PBMC) is 0.5 in women 
without RPL in the first trimester as compared to 15 in 
women with RPL [17]. 
More recent studies have demonstrated that 
kisspeptin, G - protein coupled receptor 54 (GPR54) 
and progesterone induced blocking factor (PIBF) 
expression in both syncytiotrophoblasts and 
cytotrophoblasts are decreased in women with 
recurrent pregnancy loss (RPL) as compared to 
controls (P<0.05) [18]. Also, kisspeptin, PIBF and 
progesterone receptor (PR) expressions in decidua are 
significantly decreased in women with RPL as 
compared to controls (P<0.01) [18]. 
PROGESTERONE AND EARLY PREGNANCY 
Progesterone, a female sex hormone, causes 
secretory changes in the endometrium during the 
second half of the menstrual cycle and improves its 
receptivity for successful implantation of a fertilized 
egg. Progesterone is secreted mainly by the corpus 
luteum, formed in the ovary after the follicle ruptures 
during ovulation. The window of implantation (day 6- 
day 10 post ovulation) coincides with maximum 
progesterone production by the corpus luteum with 
maximum α2, β2 integrin and osteopontin expression 
with pinopode activity at the endometrial level. The 
response of endometrium to progesterone depends not 
only on optimal progesterone seretion from the corpus 
luteum but also on adequate induction of progesterone 
receptors by oestrogen during the follicular phase. A 
deficient response to adequate levels of progesterone 
could also result from endometrial pathology like 
Asherman’s syndrome, endometritis or primary 
endometrial defect- resulting in infertility or miscarriage. 
Should pregnancy occur, HCG secreted from the 
implanting embryo rescues the corpus luteum with 
continuation of progesterone secretion and 
maintenance of early pregnancy. The leuto-placental 
shift occurs 36 days after the LH surge (at 7-8 weeks of 
gestation) when placenta takes over the function of 
secreting progesterone.  
Progesterone has been shown to aid implantation 
and maintenance of pregnancy by stabilizing the 
endometrium and inhibiting myometrial contractions 
[19]. Pregnancy involves a significant decrease in 
uterine vascular tone and an increase in uterine blood 
flow, which is mediated partly by steroid hormones, 
including oestrogen, progesterone, and cortisol. 
Progesterone induces endothelial nitric oxide synthase 
expression and activity, nitric oxide production, and 
expression of enzymes for prostacycline production, 
thereby altering uterine artery contractility and 
increasing uterine blood flow during pregnancy [20, 21]. 
An immune-modulatory role of progesterone has 
also been suggested- progesterone induced blocking 
factor (PIBF), promotes a shift from Th1-dependent pro 
inflammatory cytokines towards Th2-dependent 
protective cytokines that support pregnancy [22]. 
It has been postulated that a causative factor in 
many cases of miscarriage may be inadequate 
secretion of progesterone during the luteal phase of the 
menstrual cycle and in the early weeks of pregnancy. 
Therefore, progestogens have been used, beginning in 
the first trimester of pregnancy, in an attempt to prevent 
spontaneous miscarriages.  
There is now evidence suggesting that exogenous 
administration of progestational agents can decrease 
IFNγ-­‐ production by peripheral blood mononuclear cells 
and shift the immune system toward Th 2-dependent 
anti-inflammatory cytokines such as IL-4 and IL-6 [22]. 
Vaginal micronized progesterone treatment in women 
with threatened miscarriage was likewise shown to 
cause a potential protective shift in the cytokine 
concentration of endocervical secretions with signify- 
cant decrease in IFNγ- and increase in IL10 levels [23]. 
However a few other studies failed to show similar 
results with no significant differences in the cytokine 
expression after administration of progestin 
(dydrogesterone) in women with threatened or 
recurrent miscarriages. The authors concluded that 
dydrogesterone in the study group possibly had a 
protective effect on pregnancy through a mechanism 
that did not involve alteration of serum cytokine levels 
[24, 25]. 
PROGESTERONE IN THREATENED MISCARRIAGE 
Treatment modalities for bleeding in early weeks of 
gestation are likely be effective only when the fetus is 
viable, and has no chromosomal abnormality [26]. 
Ultrasound enables rapid and accurate establishment 
of viability of a pregnancy, with the ability to predict if a 
pregnancy is likely to continue when there is bleeding. 
Identification of fetal heart activity carries a 97% 
likelihood for the pregnancy to continue beyond 20 
weeks [27]. The therapeutic approach to women with 
threatened miscarriage can therefore be rationalized 
where ultrasound is available. 
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Most women with threatened miscarriage are 
prescribed bed rest and progesterone with limited and 
conflicting evidence for both treatment modalities [28]. 
In women presenting with threatened miscarriage, 
there is now preliminary evidence of a reduction in the 
spontaneous miscarriage rates, with the use of 
progestins. This conclusion was drawn from four RCTs 
which included 411 women. Miscarriage was 
significantly less in women receiving progestins when 
compared to placebo or no treatment (risk ratio 0.53; 
95% CI 0.35 to 0.79). There was no evidence of 
increase in the rates of antepartum haemorrhage, 
pregnancy-induced hypertension, or congenital 
abnormalities in the treatment group [29]. The authors 
however cautioned that these evidences were 
preliminary and additional well designed trials are 
required to confirm them [30]. 
A systematic review which included 660 participants 
from five dydrogesterone trials; also showed a 
statistically significant reduction of miscarriage rates 
with dydrogesterone compared to standard care in 
women with clinical diagnosis of threatened 
miscarriage. OR 0.47 (confidence interval [CI 0.31–
0.7]) [31]. 
Another meta-analysis of seven studies which 
included a total of 744 women showed a statistically 
significant reduction in miscarriage rate with 
progestogen use (RR 0.53, 95% CI: 0.39 to 0.73) [32]. 
However these studies (Table 1) were of small sample 
size and of poor quality with inadequate methodology 
[32]. 
The above mentioned trials, [33-39] although small 
and of poor quality, suggest benefit with use of 
progesterone and progesterone analogues in treatment 
of threatened miscarriage.  
Presently a large randomised double-blind, placebo-
controlled multicentre study – the PRISM trial [32] is 
underway which plans to randomize 4,150 women with 
clinical diagnosis of threatened miscarriage, and USG 
confirmation of intra-uterine gestational sac into the 
progesterone arm( 400mg of micronized progesterone 
vaginal suppositories twice daily up to 16 weeks of 
gestation) and placebo arm. The primary outcome 
measure that shall be studied is live birth rates beyond 
34 weeks, other secondary outcome measures include-
gestation at delivery; ongoing pregnancy at 12 weeks ; 
miscarriage rate; survival at 28 days of neonatal life; 
chromosomal and congenital abnormalities; adverse 
events; antenatal complications; birth weight; APGAR 
Table 1: Trials of Progestogens Versus Placebo or no Treatment for Threatened Miscarriage [33, 39] 
Study Dose and Route Duration of Treatment  Compared with  Risk Ratio (M-H fixed 95% CI) 
Misto  
1967  
n=25  
20-40 mg oral dydrogesterone  Once daily for 6 to 15 days, or for longer periods  Placebo  0.25 (0.01 4.50) 
Ehrenskjold  
1967  
n=153  
20 mg oral dydrogesterone  
20 mg BD/20 mg TDS until 
symptoms ceased/10 mg twice 
daily for5 days/5 mg twice daily 
for7 days.  
No treatment  0.68 (0.38,1.23).  
Gerhard  
1987  
n=34  
25 mg progesterone vaginal 
suppositories twice daily  
Until miscarriage or for 14 days 
after bleeding stopped.  Placebo  0.33 (0.01,7.65)  
Palagiano  
2004  
n=50  
90 mg progesterone (8%) 
vaginal suppositories  Once daily for five days.  Placebo  0.50 (0.17, 1.45) 
Omar  
2005 n=154  
dydrogesterone 40 mg 
followed by 10 mg BD Until bleeding stopped.  No treatment  0.29 (0.09, 1.02).  
El-Zibdeh 2009  
n=146  
10 mg oral dydrogesterone 
twice daily.  
From enrolment until one week 
after bleeding stopped.  No treatment  0.70 (0.37, 1.32) 
Pandian  
2009  
n=191  
dydrogesterone 40 mg oral 
followed by 10 mg twice daily Until 16 weeks of gestation.  No treatment  0.44(0.24, 0.82) 
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scores; need for resuscitation and other neonatal 
complications (such as infection, respiratory distress 
syndrome, necrotising enterocolitis).  
If effectiveness of progesterone therapy in 
threatened miscarriage is confirmed by the PRISM trial, 
women with bleeding in early weeks of pregnancy 
across the globe will benefit substantially.  
PROGESTERONE IN UNEXPLAINED RECURRENT 
PREGNANCY LOSS (RPL) 
Recurrent miscarriage defined as loss of three or 
more consecutive pregnancies affect about 1-2% of 
couples trying to conceive. Therapeutic management of 
RPL aims at correcting the underlying cause, 
unfortunately in more than 50% the cause of RPL 
remains unknown. High-quality data on management of 
RPL are limited; therefore, many recommendations are 
based upon clinical experience and data from 
observational studies or RCTs of small sample size 
[40]. 
The prognosis for a successful future pregnancy in 
couples suffering from RPL is generally good with 
overall live birth rates for unexplained RPL as high as 
77% [41]. However Increasing maternal age and a 
higher number of previous miscarriages are associated 
with a significant decrease in the likelihood of having a 
live birth. In women with recurrent early first trimester 
pregnancy loss, the presence of fetal cardiac activity is 
reassuring with increased possibility of a subsequent 
viable delivery, nonetheless risk of fetal loss in these 
women, remain above that of the general population 
(losses in women with RPL - 5 to 22 % compared to 7 
to 15 % in infertile populations and 3 to 6 % in controls) 
[42]. 
 Whether progesterone supplementation in the first 
trimester, increase the live birth rates among women 
with unexplained recurrent miscarriages, is uncertain. 
However progesterone is often prescribed to women 
with unexplained RPL, despite the lack of large 
randomized trials demonstrating its efficacy [43]. 
The Cochrane review on progesterone for 
prevention of miscarriage, [44] included progesterone 
use in both threatened and unexplained recurrent 
miscarriage. This meta-analysis of 14 trials which 
included 2158 women showed no statistically 
significant difference in miscarriage rates between 
progestogen and placebo groups (Peto odds ratio 0.99; 
95% confidence interval (CI) 0.78 to 1.24). Subgroup 
analysis on method of administration of progestogen 
(oral, intramuscular or vaginal) also showed no 
statistically significant difference between progestogen 
and placebo groups. The authors therefore concluded 
that there is no evidence to support the routine use of 
progestogen to prevent miscarriage in early to mid-
pregnancy.  
Interestingly, after making provision for previous 
obstetric history, a subgroup analysis which only 
included women who had suffered three or more 
consecutive miscarriages prior to the studied 
pregnancy, showed a statistically significant difference 
in favour of progestogen compared to placebo or no 
treatment.( risk of RPL with progesterone odds ratio 0.4 
to 0.5 [44]. However, the authors concluded that; the 
benefit of progesterone therapy in unexplained RPL 
require further studies , because of the small sample 
size , wide confidence intervals in most trials, and 
significant problems in the study designs [44]. 
A recently published double blind, randomized, 
placebo-controlled study on the effect of 
dydrogesterone on pregnancy outcome in women with 
a history of RPL, and its correlation with Th1 and Th2 
cytokine levels concluded that dydrogesterone 
significantly reduces the miscarriage rates in women 
suffering from unexplained RPL (p =0.004) when 
compared to a placebo, along with significantly 
improved age of gestation at delivery [25]. However 
these favourable outcomes were not related to 
changes in the Th1 and Th2 cytokine levels in the 
maternal plasma. In this study, 29.3% (12 of 41) 
miscarriages occurred in the first 4 weeks of 
recruitment. 24.1% [7 of 29] in the placebo group and 
41.7% [5 of 12] in the dydrogesterone group, (P>.05). 
Therefore, the benefit of dydrogesterone was uncertain 
in women who aborted within 3-4 weeks of starting the 
drug therapy, in the study group. 
Another multicenter, double-blind, placebo-
controlled, randomized trial on vaginal micronized 
progesterone use in women with recurrent 
miscarriages (PROMISE trial) concluded that 
progesterone therapy in the first trimester of pregnancy 
did not result in a significantly higher rate of live births 
among women with a history of unexplained recurrent 
miscarriages.( 65.8% (MVP) versus 63.3% (placebo) 
RR 1.04 (95% CI: 0.94, 1.15). Also no significant 
differences were observed between the treatment and 
placebo group in terms of: gestational age at delivery, 
clinical pregnancy (at 6-8 weeks), ongoing pregnancy 
(at 12 weeks), ectopic pregnancy, miscarriage rates, 
stillbirths and neonatal outcomes [45]. 
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Study limitations and conflicting results on outcome 
from different trials on use of progesterone in 
miscarriage, led to a 2015 committee opinion by the 
American Society of Reproductive Medicine that - use 
of supplemental exogenous progesterone in a non-ART 
cycles beyond the time of expected menses (i.e., 2 
weeks after ovulation) and after the confirmation of 
pregnancy is of no benefit [46]. 
SAFETY ISSUES WITH PROGESTERONE USE IN 
EARLY PREGNANCY. 
Use of any drug or hormone during early weeks of 
pregnancy i.e. during embryogenesis and organo- 
genesis require caution and a need to consider the risk 
benefit ratio for its use. There has been concern 
regarding the use of progestins in pregnancy, with 
respect to the increased risk of genital and non-genital 
anomalies. All forms of progestins have been 
implicated to approximately double the background risk 
(0.5%) of hypospadias in the male fetus [47]. There are 
insufficient data on the risk to exposed female fetuses, 
but these drugs may induce mild virilisation in them. A 
recent study has described a threefold increase in the 
risk of congenital heart disease in infants of mothers 
exposed to the progestogen- dydrogesterone in the first 
trimester of pregnancy [48]. 
 In contrast to the above studies specific analysis of 
progesterone and 17-hydroxy progesterone has not 
shown any significant teratogenic effects in large cohort 
and case-control studies, involving almost 17,695 
women [49-52]. A meta-analysis of 14 studies, 
involving 65,567 women, likewise concluded that there 
was no association between first-trimester sex 
hormone exposure and external genital malformations 
[53]. Because of the pharmacological heterogeneity of 
the progestins, the FDA in 1999 revoked its single 
class labelling [54]. The Australian Drug Evaluation 
Committee has classified natural micronized 
progesterone as a Category A drug as there are no 
proven increase in the frequency of malformations or 
any other harmful effects on the fetus [54]. 
Progesterone has been used in several studies for the 
prevention of preterm birth with no safety issues and 
was approved in February 2011 for this indication by 
the FDA. 
Concerns have been raised that due to the uterine-
relaxant properties of progesterone, there may be a 
delay in spontaneous miscarriage in women with 
fertilised defective ova or chromosomal anomaly with 
continuation of the pregnancy. However the available 
evidence does not suggest that progesterone support a 
pregnancy with chromosomally abnormal fetus. In 38 
trials (including 5,110 women) using progesterone or its 
analogues in early pregnancy for various indications, 
there was no increase in aneuploid neonates [55-57]. 
PROGESTERONE AND MATERNAL SIDE EFFECTS 
There appears to be no safety concerns for use of 
progesterone in the mother. It may be associated with 
mild side effects like somnolence, dizziness, light 
headedness, gastrointestinal disturbances, nausea, 
vomiting, fluid retention and mastalgia. Injectable forms 
may be associated with pain, inflammation, rash and 
abscess formation at the local site. Rarely more serious 
complications may occur, such as jaundice, thrombosis 
and pulmonary embolism. 
Contraindications for the use of progesterone 
include- 
Liver tumours, breast or genital cancers, severe 
arterial disease, acute porphyria , history of pregnancy 
with cholestasis, severe pruritus or pemphigoid 
gestationalis. 
CONCLUSION 
10-15% of clinical pregnancies miscarry. In a vast 
majority the cause of miscarriage remain unknown. 
Progesterone is crucial for implantation, establishment 
and continuation of pregnancy. It has been suggested 
that a causative factor in many cases of miscarriage 
may be inadequate secretion of progesterone during 
the luteal phase of the menstrual cycle and in the early 
weeks of pregnancy. Progesterone and progestogen 
analogues have often been used, beginning in the first 
trimester of pregnancy, in an attempt to prevent 
spontaneous miscarriage.  
In women presenting with a clinical diagnosis of 
threatened miscarriage, there is preliminary evidence 
of a reduction in the rate of spontaneous miscarriage 
with the use of progesterone. Larger RCTs may help to 
further validate these findings. Initial reports of 
favourable outcome with use of progesterone in RPL 
could not be confirmed uniformly by larger randomized 
trials. Study limitations and conflicting results from 
different trials, led to a 2015 committee opinion that use 
of supplemental exogenous progesterone in a non-ART 
cycle beyond the time of expected menses and after 
the confirmation of pregnancy is of no benefit.  
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